1. Home
  2. PCN vs WVE Comparison

PCN vs WVE Comparison

Compare PCN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Strategy Fund

PCN

Pimco Corporate & Income Strategy Fund

HOLD

Current Price

$11.06

Market Cap

880.2M

Sector

Finance

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$4.24

Market Cap

957.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCN
WVE
Founded
N/A
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
880.2M
957.7M
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
PCN
WVE
Price
$11.06
$4.24
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$29.81
AVG Volume (30 Days)
406.1K
2.9M
Earning Date
01-01-0001
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$85.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$11.06
$4.31
52 Week High
$13.49
$21.73

Technical Indicators

Market Signals
Indicator
PCN
WVE
Relative Strength Index (RSI) 22.63 28.19
Support Level N/A N/A
Resistance Level $12.07 $6.33
Average True Range (ATR) 0.11 0.21
MACD -0.06 -0.03
Stochastic Oscillator 6.98 3.38

Price Performance

Historical Comparison
PCN
WVE

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: